Hyperviscosity syndrome remains one of the most critical complications of this disorder, occurring when excessive amounts of IgM monoclonal protein cause the blood to thicken. This condition can lead to neurological symptoms, visual disturbances, and cardiovascular strain if not addressed promptly. In late 2025, plasmapheresis, or therapeutic plasma exchange, continues to be the primary emergency intervention used to rapidly reduce the concentration of these proteins and restore normal blood flow.

The Waldenstrom Macroglobulinemia Sector highlights that while plasmapheresis is highly effective at providing immediate symptomatic relief, it does not treat the underlying malignancy. Therefore, it is typically used as a bridge to systemic therapies that target the production of the abnormal protein at its source. Modern apheresis technology has become more efficient, allowing for safer and faster procedures in specialized hematology units.

Effective management of blood viscosity is essential for preventing long-term organ damage, particularly in the kidneys and the central nervous system. Clinical guidelines now emphasize the early recognition of hyperviscosity symptoms to ensure that patients receive this life-saving intervention before irreversible complications occur. As diagnostic monitoring becomes more frequent, the proactive use of plasma exchange is helping to stabilize high-risk patients more effectively.

Frequently Asked Questions

Q. What are the symptoms of hyperviscosity? A. Common signs include persistent headaches, blurred vision, dizziness, and a feeling of general fatigue or mental confusion.

Q. Is plasmapheresis a permanent cure? A. No, it is a temporary procedure to thin the blood; it must be followed by systemic medical treatment to control the underlying disease.

explore our related reports